Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Jong Choi

Pain Medicine Tucker, GA Medical Doctor

NPI 1295845584 CMS profile 104447

2060 Northlake Pkwy, Tucker, GA 30084

Open in the dashboard

General payments

$2,341

206 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Jong Choi of Tucker, GA is reported in the CMS Open Payments database as having received $2,341 across 206 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $56 4
2021 General $680 66
2020 General $490 47
2019 General $1,115 89

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jong Choi
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Jong Choi were reported at $0. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Jong Choi Pain Medicine median Middle half National median
2019 $1,115 $409 $115–$1,311 $163
2020 $490 $214 $66–$666 $114
2021 $680 $299 $84–$899 $132
2022 $56 $335 $103–$1,149 $149
2023 $0 $376 $114–$1,228 $160
2024 $0 $387 $115–$1,173 $164
2025 $0 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,076 90 payments
  2. Collegium Pharmaceutical, Inc. $515 61 payments
  3. Daiichi Sankyo Inc. $204 16 payments
  4. Pfizer Inc. $176 17 payments
  5. Sentynl Therapeutics, Inc. $101 7 payments
  6. Biodelivery Sciences International, Inc. $97 6 payments
  7. RedHill Biopharma Inc. $76 5 payments
  8. Scilex Pharmaceuticals Inc. $57 1 payment
  9. ASSERTIO THERAPEUTICS, Inc. $14 1 payment
  10. Takeda Pharmaceuticals U.S.A., Inc. $13 1 payment
  11. Other $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $2,333 205 payments
  2. Education $8 1 payment
Products named General payments · program years 2019–2022
  1. RELISTOR Gastroenterology $1,076 90 payments
  2. XTAMPZA $507 60 payments
  3. RELISTOR Gastroenterology $300 21 payments
  4. LUCEMYRA $251 18 payments
  5. Morphabond ER $204 16 payments
  6. LYRICA $130 14 payments
  7. FLECTOR PATCH $115 13 payments
  8. Levorphanol Tartrate $101 7 payments
  9. EMBEDA $90 11 payments
  10. Movantik $76 5 payments
  11. Other $433 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

206 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record